11 completed, 4 unknown, 3 withdrawn, 2 active not recruiting. 12 Phase 2, 9 Not applicable, 1 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 12 | Completed 4, Unknown 4, Active not recruiting 1, Recruiting 1, Terminated 1, Withdrawn 1 |
| Not applicable | 9 | Completed 6, Withdrawn 2, Active not recruiting 1 |
| Phase 3 | 1 | Completed 1 |
Follow Sheppard Pratt Health System: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Effects of Cannabidiol on Psychiatric Symptoms, Cognition, and Cannabis Consumption in Cannabis Users With Recent-Onset Psychosis Cannabidiol (CBD), Placebo - Schizophrenia Spectrum Disorders, Cannabis Use | Phase 2 | Withdrawn | University of Maryland, Baltimore | 2050-01-01 | 2021-04-19 | |
| Pilot Testing a Digital Intervention to Improve Smoking Cessation in Persons With Serious Mental Illness BecomeAnEX, Usual Care - Tobacco Cessation | Not applicable | Completed | University of Maryland, Baltimore | 59 | 2022-09-06 | 2026-07-15 |
| The Safety and Efficacy of Psilocybin in Patients With Treatment-resistant Depression and Chronic Suicidal Ideation Psilocybin - Treatment Resistant Depression, Suicidal Ideation | Phase 2 | Completed | Sheppard Pratt Health System | 20 | 2022-03-28 | 2025-12-24 |
| Synbiotic Compound to Reduce Symptoms of Schizophrenia Synbiotic Supplement, Inert Compound - Schizophrenia, Schizoaffective Disorder | Phase 2 | Recruiting | Sheppard Pratt Health System | 68 | 2022-02-21 | 2026-04-07 |
| The R-CITY Project: A Collaborative Intervention With Teachers and Youth Second Step + R-CITY, Second Step Only - Violence | Not applicable | Active not recruiting | University of Virginia | 145 | 2021-09-15 | 2026-01-12 |
| Coaching Teachers in Bullying Detection and Intervention Bullying Classroom Check-Up (BCCU) - Intervention, Control | Not applicable | Completed | Johns Hopkins Bloomberg School of Public Health | 34 | 2021-06-01 | 2026-04-08 |
| An Open Label Study of the Safety and Efficacy of Psilocybin in Participants With Treatment-Resistant Depression (P-TRD) Psilocybin - Treatment Resistant Depression | Phase 2 | Unknown | Sheppard Pratt Health System | 27 | 2021-03-01 | 2024-08-09 |
| The Safety and Efficacy of Psilocybin in Participants With Type 2 Bipolar Disorder (BP-II) Depression. Psilocybin - Treatment Resistant Depression | Phase 2 | Unknown | Sheppard Pratt Health System | 15 | 2021-03-01 | 2022-10-25 |
| Development of a Scalable Intervention to Improve Smoking Cessation in Persons With Serious Mental Illness BecomeAnEx - Tobacco Cessation | Not applicable | Withdrawn | University of Maryland, Baltimore | 2020-07-01 | 2020-11-06 | |
| Probiotics to Prevent Relapse After Hospitalization for Bipolar Depression Probiotic Supplement, Inert Compound - Bipolar Depression | Phase 2 | Active not recruiting | Sheppard Pratt Health System | 80 | 2018-12-11 | 2026-04-07 |
| A Trial Evaluating Effects of COMT Inhibition in Patients With Acquired Brain Injury Tolcapone 200 MG, Placebo - Brain Injuries, Brain Injuries, Traumatic | Phase 2 | Unknown | Sheppard Pratt Health System | 16 | 2017-07-20 | 2017-09-06 |
| Sulforaphane to Reduce Symptoms of Schizophrenia Sulforaphane Nutraceutical, Identical-appearing Placebo - Schizophrenia, Schizoaffective Disorder | Phase 2 | Completed | Sheppard Pratt Health System | 64 | 2017-02-22 | 2021-07-27 |
| An Open Label Trial of TMS Therapy for Bipolar Depression NeuroStar TMS - Bipolar Depression | Not applicable | Completed | Sheppard Pratt Health System | 31 | 2015-12-01 | 2022-06-01 |
| Evaluate the Effects of Tolcapone on Cognitive and Behavioral Dysfunction in Patients With BI and NCD Tolcapone - Brain Injuries, Traumatic, Neurocognitive Disorders | Phase 2 | Unknown | Sheppard Pratt Health System | 100 | 2015-11-01 | 2017-01-19 |
| Galantamine and Memantine Combination for Cognitive Impairments in Schizophrenia Galantamine ER, Memantine XR - Schizophrenia, Schizoaffective Disorder | Phase 2 | Terminated | Sheppard Pratt Health System | 3 | 2014-09-01 | 2017-11-09 |
| A Double-Blind Trial of Adjunctive Valacyclovir to Improve Cognition in Early Phase Schizophrenia Valacyclovir HCI 500 mg tablets, placebo - Schizophrenia | Phase 2 | Completed | Indiana University | 170 | 2014-03-26 | 2019-01-30 |
| Supplemental Transcranial Magnetic Stimulation (TMS) vs. Standard Medication Monotherapy for Treating Major Depression: An Exploratory Field Study Supplemental TMS, Standard Medication Monotherapy - 1. Major Depressive Disorder | Not applicable | Withdrawn | Sheppard Pratt Health System | 2013-09-01 | 2017-04-25 | |
| Probiotics to Prevent Relapse After Hospitalization for Mania Probiotic Supplement, Inert Compound - Bipolar Disorder, Schizoaffective Disorder | Not applicable | Completed | Sheppard Pratt Health System | 66 | 2012-11-01 | 2019-01-07 |
| Investigating tDCS as a Treatment for Unipolar and Bipolar Depression Sham tDCS device, Soterix tDCS device - Unipolar Depression, Bipolar Depression | Phase 2 / Phase 3 | Completed | The University of New South Wales | 120 | 2012-06-01 | 2015-12-02 |
| Double-Blind Trial of a Probiotic Supplement to Reduce the Symptoms of Schizophrenia Probiotic Supplement, Identical-appearing Placebo - Schizophrenia, Schizoaffective Disorder | Not applicable | Completed | Sheppard Pratt Health System | 65 | 2010-08-01 | 2019-02-05 |
Showing 20 of 22. Sign in to see all of them.
Psychotic Disorders (8) · Schizophrenia (7) · Bipolar Disorder (4) · Depressive Disorder, Treatment-Resistant (3) · Brain Injuries (2) · Brain Injuries, Traumatic (2) · Depressive Disorder, Major (2) · Tobacco Use Cessation (2) · Aggression (1) · Brain Injury, Chronic (1) · Bullying (1) · Cognitive Dysfunction (1) · Depressive Disorder (1) · Major Depressive Disorder 1 (1) · Mania (1)
Psilocybin (3) · Tolcapone (2) · Cannabidiol (1) · Galantamine (1) · Memantine (1) · Transcranial Magnetic Stimulation (1) · artemisinin (1)
United States (21) · Australia (1)
Faith Dickerson, PhD, MPH (4) · Scott Aaronson, MD (3) · Faith B Dickerson, PhD, MPH (2) · Robert J Schloesser, MD (2) · Scott T Aaronson, MD (2) · Alan Breier, MD (1) · Brent Wurfel, MD, PhD (1) · Deepak D'Souza, MD (1) · Diane Highum, MD (1) · Elise Pas, PhD (1) · Evagelos Coskinas, MD, PhD (1) · Faith Dickerson, PhD (1) · Gerald Maguire, MD (1) · Keith Nuechterlein, PhD (1) · Maju M. Koola, MD (1)
PMID 21546216, PMID 24940526, PMID 28705532, PMID 29111077, PMID 29693757, PMID 30172724, PMID 30478008, PMID 38055270, PMID 38780536, PMID 39343309, PMID 39741440, PMID 40499827, PMID 42138588, PMID 42248535
R01HD102491 (1)